Sharechat Logo

Ebos raises $175m, more than it sought from underwritten placement

Wednesday 1st May 2019

Text too small?

Ebos says it has raised $175 million from a discounted placement to institutions, $25 million more than it had been seeking.

Chair Mark Waller says the issue was increased to accommodate strong demand from both existing and new institutional investors in New Zealand, Australia and offshore.

“Our strategy has clearly resonated with investors,” Waller says in a statement.

“We look forward to continuing to successfully grow both our healthcare and animal care segments to create further shareholder value.”

Following the placement, Ebos’ pro-forma net debt-to-ebitda (earnings before interest, tax, depreciation and amortisation) ratio will fall to 1.51 times at Dec. 31 from 2.16 times.

Chief executive John Cullity says the proceeds “provide Ebos with with enhanced financial capacity for further strategic acquisitions and organic growth initiatives to continue the long-term growth of the group.”

When the placement was announced yesterday, Cullity said Ebos is considering a number of bolt-on acquisitions to both its healthcare and animal care operations, including healthcare consumer brands, medical devices and pharmacy sector expansion.

He said several organic growth opportunities may also require capital, including funding the development of existing brands into new growth markets such as Asia. 

The new shares will be allotted on Monday at $19.70 per share, an 8 percent discount to the closing price on NZX on April 29. UBS New Zealand was the sole lead manager and underwriter for the placement.

Ebos’ statement didn’t say why underwriting was necessary or how much UBS charged.

(BusinessDesk)



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

NZ dollar stalled; US-China trade deal may be postponed
AFT Pharmaceuticals starts to hit its straps
Crown seeks US$100m from Tui operator; Prospector moving on
Pacific Edge goes back to shareholders for another $20m
Crown seeks $100m from Tui operator Tamarind
Ryman underlying annual profit may rise by up to 17%
NZ dollar eases on increasing US-China doubts, lack of news in Fed minutes
From dog tucker to top dog: economists ask how Northport can be Auckland’s best replacement
MARKET CLOSE: NZ shares rise; Metlife jumps on takeover talk
NZ dollar eases on technical factors, buoyed by higher dairy prices

IRG See IRG research reports